Compass Therapeutics, Inc.
CMPX
$2.25
-$0.01-0.44%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.15% | 60.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.91% | 12.83% | |||
| Operating Income | -32.91% | -12.83% | |||
| Income Before Tax | -37.33% | -16.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -37.33% | -16.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -37.33% | -16.55% | |||
| EBIT | -32.91% | -12.83% | |||
| EBITDA | -32.90% | -12.86% | |||
| EPS Basic | -37.03% | -15.65% | |||
| Normalized Basic EPS | -37.13% | -15.63% | |||
| EPS Diluted | -37.03% | -15.65% | |||
| Normalized Diluted EPS | -37.13% | -15.63% | |||
| Average Basic Shares Outstanding | 0.21% | 0.84% | |||
| Average Diluted Shares Outstanding | 0.21% | 0.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||